Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Flyte Aviation, Inc.RMED · Entity 8648 | Director | June 04, 2021 | June 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Flyte Aviation, Inc.
Report date June 04, 2021 · Filed June 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,410 |
Reported balance
After 2021-06-04 transaction · row 1
1 source rowRow 1 · 2021-06-04 · Grant · Acquired 4,000 · Balance 8,410 F1: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) June 4, 2022, or (ii) the day prior to the date of the Stockholder's Annual Meeting next following June 4, 2021, subject to the reporting person's continued service. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,000 |
Reported balance
Holding disclosure · report date 2021-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,000 F2: Shares held of record by the Thomas & Joan Stafslien Family B Trust dated 6/17/1997, for which the reporting person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) June 4, 2022, or (ii) the day prior to the date of the Stockholder's Annual Meeting next following June 4, 2021, subject to the reporting person's continued service.
F2: Shares held of record by the Thomas & Joan Stafslien Family B Trust dated 6/17/1997, for which the reporting person serves as trustee.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NUVASIVE INC
Report date December 31, 2018 · Filed February 07, 2019
Section 16 reporting ended · disclosed 2019-02-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| PRSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 7,929 |
Reported balance
After 2018-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-07 · Grant · Acquired 7,929 · Balance 7,929 F1: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: This PRSU award was granted to the Reporting Person on March 1, 2017. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2017. On February 7, 2018, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 7,929 shares on March 1, 2020, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Due to an administrative error, a Form 4 reporting the certification of the performance condition was not filed in February 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: This PRSU award was granted to the Reporting Person on March 1, 2017. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2017. On February 7, 2018, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 7,929 shares on March 1, 2020, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Due to an administrative error, a Form 4 reporting the certification of the performance condition was not filed in February 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2021 Filed Jun 8, 2021 20:06 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039054 · doc4.xml · nonDerivative · entry 1 Stafslien Joan · CIK 0001467816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,410 F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) June 4, 2022, or (ii) the day prior to the date of the Stockholder's Annual Meeting next following June 4, 2021, subject to the reporting person's continued service. Read SEC document |
| November 19, 2020 Filed Nov 19, 2020 18:29 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | PurchaseCommon Stock | 4,410 | $5.67 | $25,002.50 |
DisclosureSEC source: 0001209191-20-059505 · doc4.xml · nonDerivative · entry 1 Stafslien Joan · CIK 0001467816 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,410 F1 · price: Represents the weighted average share price of an aggregate total of 4,410 shares purchased in the price range of $5.54 to $5.80 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: Shares held of record by the Thomas & Joan Stafslien Family B Trust dated 6/17/1997, for which the reporting person serves as trustee. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 17:57 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054824 · doc4.xml · nonDerivative · entry 1 Stafslien Joan · CIK 0001467816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) October 12, 2021, or (ii) the day prior to the date of the Annual Meeting next following October 12, 2020, subject to the reporting person's continued service. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 09:04 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-026094 · doc4.xml · nonDerivative · entry 1 Stafslien Joan · CIK 0001467816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Reported shares are represented by restricted stock units ("RSUs"), and each RSU is the economic equivalent of one share of Ra Medical Systems, Inc. common stock. Beginning on April 24, 2021, 1/3 of the RSUs shall vest annually, so that the RSUs will be fully vested on April 24, 2023, subject to the reporting person's continued service through each such vesting date. Read SEC document |
| February 07, 2018 Filed Feb 7, 2019 17:56 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 7,929 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008195 · doc5.xml · derivative · entry 1 Stafslien Joan · CIK 0001467816 · Former EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,929 Underlying: Common Stock · 7,929 shares Expires not disclosed F1 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2017. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2017. On February 7, 2018, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 7,929 shares on March 1, 2020, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Due to an administrative error, a Form 4 reporting the certification of the performance condition was not filed in February 2018. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2017. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2017. On February 7, 2018, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 7,929 shares on March 1, 2020, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Due to an administrative error, a Form 4 reporting the certification of the performance condition was not filed in February 2018. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 17:56 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 7,550 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009693 · doc4.xml · derivative · entry 1 Stafslien Joan · CIK 0001467816 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,550 Underlying: Common Stock · 7,550 shares Expires not disclosed F1 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on October 3, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on October 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on October 3, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on October 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 18:03 UTC | NUVASIVE INC NUVA · Entity 110002 | PurchaseCommon Stock | 5,000 | $59.68 | $298,400.00 |
DisclosureSEC source: 0001209191-16-148029 · doc4.xml · nonDerivative · entry 1 Stafslien Joan · CIK 0001467816 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 5,000 F1 · price: Weighted average purchase price from purchase transactions ranging from $59.40 to $59.80. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will undertake to provide full information regarding the number of shares purchased at each separate price. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to Issuer equity awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.